Biopharmaceutical research and development company that's an affiliate of Clover Health
Developer of mRNA-based pathway activity profiling technology designed to revolutionize precision medicine by obtaining more insight into the mechanisms of disease. The company offers to utilize its extensive database with pathway activity profiles to support diagnostics and drug development, providing researchers with qPCR tests for decentralized use via a service testing facility in The Netherlands.
22seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline. It was established in Cambridge, Massachusetts in 2021.
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.
Fluidigm Corporation develops and markets innovative technologies and tools for life sciences research globally. The company specializes in integrated fluidic circuits that control fluids at the nanoscale, enabling a range of applications in biological research. Its product offerings include analytical systems such as the Helios CyTOF system, the Hyperion imaging system, and the Biomark HD system, along with various assays and reagents designed for immuno-oncology and genetic analysis. Fluidigm also provides preparatory instruments and single-cell microfluidics, such as the C1 and Polaris systems. The company serves a diverse clientele, including academic institutions, clinical research laboratories, biopharmaceutical, biotechnology, and agricultural biotechnology companies, focusing on non-diagnostic and non-clinical applications. Established in 1999 as Mycometrix Corporation, it adopted the name Fluidigm Corporation in 2001 and is headquartered in South San Francisco, California.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.
Nplex Biosciences is a biotechnology company based in the United States that specializes in proteomic technology. The company has developed a platform that utilizes DNA nanotechnology to understand, detect, and treat diseases. Nplex offers a range of instruments and automation tools for measuring multiple proteins from blood samples, providing cost-effective solutions for protein data analysis. Its technology integrates seamlessly with industry-standard cytometers, enabling high-throughput analysis and the development of custom protein panels. Nplex aims to enhance existing instruments and workflows while facilitating automation in proteomic research and applications.
Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.
Operator of a biopharmaceutical company intended to discover and develop next-generation medicines for neurodegenerative diseases. The company is focused on developing small-molecule activators of glucocerebrosidase and advanced programs targeting the innate immune system that can accelerate the progression of several neurological diseases, enabling healthcare professionals to transform the lives of patients with treatments for various ailments.
Xcell Biosciences, Inc. is a San Francisco-based life science company founded in 2012 that focuses on developing innovative technologies for cancer cell analysis and immunotherapy. The company specializes in a proprietary bench-top system that allows for the capture, growth, and analysis of primary cells directly from patient blood samples. This technology is designed to enhance the control of cell phenotype and function, thereby optimizing the efficacy and persistence of immune cell therapies. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences aims to empower researchers with advanced tools for cell maintenance and expansion, ultimately facilitating predictive therapy development and improving clinical outcomes.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.
SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
NanoCellect Biomedical, Inc. develops innovative flow cytometry and cell sorting technology aimed at enhancing the capabilities of life science researchers in cellular analysis, molecular diagnostics, and personalized medicine. Founded in 2009 and based in San Diego, California, the company offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to facilitate cell sorting while minimizing biohazard risks and shear stress commonly associated with traditional methods. By making flow cytometry more affordable and accessible, NanoCellect aims to support biomedical researchers in analyzing and isolating cells efficiently, thereby promoting significant advancements in drug discovery and diagnostics. The company's technology is designed to provide rapid, objective, and quantitative data on individual cells, empowering scientists to conduct essential research with greater ease and precision.
TMRW Life Sciences is a developer of a cryo-storage platform intended to improve the success rates of assisted reproductive technology. The company's platform offers an in-clinic robotic storage system and a fully digital chain of custody from clinic to offsite longterm storage, continuous remote and local monitoring and electronically integrated processes characterized by digital health signals received from every oocyte and embryo daily, enabling clients to streamline embryology lab operations, eliminate manual steps and integrates digital quality control.
Hexagon Bio, Inc. is a biotechnology company based in Menlo Park, California, that specializes in mining genomic data from fungal genomes to develop targeted small molecule therapeutics for diseases with unmet medical needs. Founded in 2016, the company leverages a proprietary platform that integrates data science, synthetic biology, and automation to discover and engineer novel drugs. By focusing on evolutionarily refined molecules and their corresponding protein targets, Hexagon Bio aims to identify and develop new medicines from the global metagenome, ultimately striving to enhance patient outcomes through innovative therapeutic solutions.
23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.
Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.
Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.
Apton Biosystems, Inc., founded in 2012 and based in Pleasanton, California, operates within the biotechnology sector, focusing on innovative solutions for genetic analysis. The company has developed a high-throughput and low-cost sequencing platform that enhances the availability of genetic testing, facilitating biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems reimagines optical systems for sequencing and single-molecule protein detection, utilizing super-resolution technology to evaluate closely spaced molecules. This approach enables the healthcare sector to create well-defined nanostructures, addressing spatial challenges and advancing high-density sequencing and protein detection capabilities. Through these advancements, Apton Biosystems contributes to the fields of preventive health and precision medicine.
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.
AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.
Developer of a multi-omic platform designed to accelerate advancements in life science and medicine. The company's platform leverages DNA nanotechnology to develop solutions for biomedical applications by providing comprehensive data, thereby enabling doctors and patients to get an accurate and complete view of an individual's biochemistry with a single test.
Octave Bioscience is an early-stage molecular diagnostics company based in Menlo Park, California, that specializes in neurodegenerative diseases, particularly multiple sclerosis. Co-founded in 2013 by Melinda Thomas and William Hagstrom, the company has developed a clinical platform that generates, analyzes, and integrates data to transform the care of neurodegenerative conditions. This platform adopts a multi-dimensional approach aimed at reducing overall healthcare costs through the optimization of medication use and healthcare services. Additionally, Octave's technology supports the pharmaceutical industry by enhancing the drug discovery process, clinical trials, and post-marketing activities through real-world evidence.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.
SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.
A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses. We utilize an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses.
Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Biopharmaceutical research and development company that's an affiliate of Clover Health
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics. The company's focus is to identify individuals and populations around the world who are extreme outliers for traits of medical relevance and to use innovative sequencing and analytic approaches to identify genes and pathways linked to these traits.
It was founded in 2018 and headquartered in Seattle, Washington.
Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.
Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.
Singular Bio, Inc. is a San Francisco-based company founded in 2012 that specializes in diagnostic testing for personalized medicine. The company has developed a cutting-edge technology for single molecule analysis of DNA, which offers exceptional sensitivity in detecting various common health conditions. Singular Bio's proprietary detection system aims to address the needs of high-volume healthcare testing, combining the accuracy of genetic analysis with the affordability and rapid results typically associated with screening tests. By leveraging advanced optics alongside custom molecular biology and chemistry, Singular Bio seeks to enhance healthcare accessibility and enable early detection of medical conditions for a broader population. As of mid-2019, Singular Bio operates as a subsidiary of Invitae Corporation.
Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.
GenapSys, Inc. develops innovative DNA sequencing technologies for applied genomic testing and medical sequencing. The company's primary product, the GenapSys Sequencer, utilizes electrical-based detection for single nucleotide incorporations, facilitating sequencing in various laboratory settings and automating clonal amplification. GenapSys offers solutions for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. Additionally, the company seeks to collaborate with local health agencies and researchers to enhance access to sequencing insights, particularly for controlling and mitigating outbreaks. The compact and portable nature of the sequencer allows it to operate from standard power sources, making it suitable for deployment in hospitals, airports, and public transportation hubs to provide rapid results for virus samples. Founded in 2010, GenapSys is headquartered in Redwood City, California.
Helix is a prominent population genomics company that operates at the intersection of clinical care, research, and data analytics. The company provides an end-to-end platform designed to facilitate genomic research and the incorporation of genomic data into healthcare practices. Helix operates one of the largest CLIA/CAP-certified next-generation sequencing laboratories and utilizes its proprietary Exome+™ assay to support various aspects of population genomics. These include recruitment and engagement, clinically actionable disease screening, and the return of results. Additionally, Helix engages in large-scale genetic analysis and viral surveillance, delivering actionable genetic insights that aid health systems, life sciences companies, payers, and government entities in enhancing patient care and informing public health decisions.
23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.
Syros Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead candidates, SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing Phase II trials for specific patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I trials for select advanced solid tumors. Syros employs a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to map gene regulatory circuits and modulate gene expression, positioning itself as a leader in gene control research. Additionally, Syros has established collaborations, including a target discovery agreement with Incyte Corporation focused on myeloproliferative neoplasms, and a licensing agreement with TMRC Co. Ltd. for tamibarotene's development and commercialization. Founded in 2011, Syros Pharmaceuticals aims to address significant unmet medical needs in oncology and beyond.
23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.
Voyager Therapeutics is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe neurological diseases. The company's lead candidate, VY-AADC, is currently undergoing an open-label Phase 1b clinical trial for Parkinson's disease. In addition to this, Voyager's preclinical pipeline includes therapies targeting amyotrophic lateral sclerosis, Huntington's disease, Friedreich's ataxia, and various tauopathies and synucleinopathies, which encompass conditions like Alzheimer's disease and Lewy Body Dementia. Voyager Therapeutics emphasizes advancing adeno-associated virus (AAV) gene therapy through innovations in vector optimization, dosing techniques, and production processes. The company has established strategic collaborations with the University of Massachusetts and ClearPoint Neuro, along with partnerships with Brammer Bio and Fujifilm Diosynth Biotechnologies to enhance its gene therapy programs. Furthermore, Voyager has a collaboration agreement with Neurocrine Biosciences for the research, development, and commercialization of AAV-based gene therapies. Founded in 2013, Voyager Therapeutics is committed to addressing critical unmet medical needs in the field of central nervous system disorders.